The Trump administration may cut off federal funding to hospitals that provide gender-related treatments to children and ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

In a paper released in Addiction, scientists reported that people with a history of alcohol use disorder who were prescribed these medications were 50% less likely to binge drink. The results were ...

SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...

G protein-coupled receptors (GPCRs) represent the targets of more than 30% of the drugs currently on the market. However, ...

Those taking effect immediately range from enhancing the state’s water infrastructure to addressing education issues, including grades in K-12 and higher education.

In the first half of 2025, researchers around the world have published a wave of peer-reviewed studies examining the effects ...

Speaker Johnson is now staring down Senate tax writers who are doubling down on threats to scale back his carefully ...

Breaking News Medicine ‘Exciting’ new non-opioid painkiller shows promising results — and doesn’t build up tolerance By Tracy Swartz Published June 3, 2025, 2:09 p.m. ET ...

Neurotensin receptor 1 (NTR1) A protein found on nerve cells that can modulate pain when activated. It is considered a promising target for developing non-opioid pain treatments. Biased agonism A ...

When mice are full and eat sugar, these nerve cells not only release signaling molecues that stimulate satiety, but also one of the body's own opiate: ß-endorphin.

When they blocked opioid signaling from POMC neurons to the PVT, sugar intake dropped significantly. The mice, despite being fed, no longer exhibited a strong preference for sweet foods.